World's First CAR-T Therapy for Solid Tumors Approved by Jiahui International Cancer Center
On June 25, 2026, the Jiahui International Cancer Center (JICC) announced a groundbreaking achievement with the approval of Satri-cel (CT041, Kaileimei®), marking the first CAR-T therapy authorized for the treatment of solid tumors. This monumental step forward in cancer treatment has the potential to bring hope to patients suffering from advanced gastric adenocarcinoma or gastroesophageal junction tumors that are Claudin18.2-positive and HER2-negative, particularly to those who have exhausted at least two previous lines of treatment.
The Satri-cel therapy received its approval from the National Medical Products Administration (NMPA) of China, positioning the JICC at the forefront of oncology care. This center not only serves local patients but also opens its doors to international patients, facilitating access to innovative therapies through a multidisciplinary approach to cancer management.
In recent years, JICC has treated individuals from various countries and regions, reflecting a growing global interest in the cancer treatments available within China. The approval of the world's first CAR-T therapy for solid tumors is expected to further escalate international demand for cutting-edge oncology innovations emerging from the country.
Dr. Linli Xuan, head of the medical oncology department at JICC, stated, 'The approval of Satri-cel represents a major advance for both patients and the global oncology community. The successful application of CAR-T cell therapy in treating solid tumors has been a significant challenge in oncology. This major breakthrough not only provides new hope for patients with advanced gastric cancer but also underscores China's growing role in pioneering revolutionary cancer treatments.'
JICC offers a comprehensive range of oncology services, including medical oncology, surgical oncology, radiation oncology, precision medicine, and advanced cellular therapies. Through specialized consultations, multilingual coordination, and streamlined care pathways, the center ensures that patients from all over the world can access the most recent advancements in cancer treatment.
This innovative CAR-T therapy, aimed at solid tumors, not only opens new therapeutic avenues for cancer patients but also exemplifies the pace at which the oncology field is evolving, especially in China. JICC remains committed to providing comprehensive and personalized care, enabling patients to benefit from these groundbreaking innovations.
For international patient inquiries, JICC has set up support services that include multi-language assistance and tailored treatment planning. The center aims to facilitate access to top-tier cancer care globally, ensuring that patients who meet specific criteria can receive the revolutionary Satri-cel therapy and other advanced treatments available.
With strong dedication to research and patient-centric care, JICC is poised to lead in the development and implementation of advanced oncology solutions that promise to transform cancer treatment outcomes. For more detailed information, visit Jiahui Health.
The Satri-cel therapy received its approval from the National Medical Products Administration (NMPA) of China, positioning the JICC at the forefront of oncology care. This center not only serves local patients but also opens its doors to international patients, facilitating access to innovative therapies through a multidisciplinary approach to cancer management.
In recent years, JICC has treated individuals from various countries and regions, reflecting a growing global interest in the cancer treatments available within China. The approval of the world's first CAR-T therapy for solid tumors is expected to further escalate international demand for cutting-edge oncology innovations emerging from the country.
Dr. Linli Xuan, head of the medical oncology department at JICC, stated, 'The approval of Satri-cel represents a major advance for both patients and the global oncology community. The successful application of CAR-T cell therapy in treating solid tumors has been a significant challenge in oncology. This major breakthrough not only provides new hope for patients with advanced gastric cancer but also underscores China's growing role in pioneering revolutionary cancer treatments.'
JICC offers a comprehensive range of oncology services, including medical oncology, surgical oncology, radiation oncology, precision medicine, and advanced cellular therapies. Through specialized consultations, multilingual coordination, and streamlined care pathways, the center ensures that patients from all over the world can access the most recent advancements in cancer treatment.
This innovative CAR-T therapy, aimed at solid tumors, not only opens new therapeutic avenues for cancer patients but also exemplifies the pace at which the oncology field is evolving, especially in China. JICC remains committed to providing comprehensive and personalized care, enabling patients to benefit from these groundbreaking innovations.
For international patient inquiries, JICC has set up support services that include multi-language assistance and tailored treatment planning. The center aims to facilitate access to top-tier cancer care globally, ensuring that patients who meet specific criteria can receive the revolutionary Satri-cel therapy and other advanced treatments available.
With strong dedication to research and patient-centric care, JICC is poised to lead in the development and implementation of advanced oncology solutions that promise to transform cancer treatment outcomes. For more detailed information, visit Jiahui Health.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.